T-502 is under clinical development by Inmunotek and currently in Phase III for Allergic Rhino-Conjunctivitis. According to GlobalData, Phase III drugs for Allergic Rhino-Conjunctivitis have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how T-502’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

T-502 overview

T-502 is under development for the treatment of rhinitis and rhinoconjunctivitis against mite allergy and allergic asthma. Allergen is administered subcutaneously and sublingually as a solution. The drug candidate is a mannosylated mixture of Dermatophagoides pteronyssinus and Dermatophagoides farina allergen extract.

Inmunotek overview

Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.

For a complete picture of T-502’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.